Liposomal forms of anticancer agents beyond anthracyclines: present and future perspectives

Area of Science:

• Pharmacology
• Drug Delivery Systems
• Oncology

Background:

• Liposomes are established drug delivery systems, particularly for cytotoxic agents.
• Encapsulation in liposomes enhances drug properties, improving therapeutic index and patient outcomes.
• Approved liposomal drugs include vincristine (intravenous) and cytarabine (intrathecal).

Purpose of the Study:

• To review the clinical use, pharmacology, and safety of less common liposomal anticancer agents.
• To compare liposomal formulations with their conventional counterparts.
• To present data on the clinical development of other emerging liposomal anticancer drugs.

Main Methods:

• Literature review of clinical studies and pharmacological data.
• Comparative analysis of liposomal versus conventional anticancer drug formulations.
• Examination of safety profiles and therapeutic outcomes.

Main Results:

• Liposomal cytarabine and vincristine are approved but less recognized than liposomal anthracyclines due to specific indications and regional approvals (US).
• Liposomal formulations generally offer improved pharmacological properties and safety.
• Ongoing clinical development shows promise for additional liposomal anticancer agents.

Conclusions:

• Liposomal anticancer drugs, including less common ones, offer significant therapeutic advantages.
• Further research and broader clinical application of liposomal formulations are warranted.
• Liposomal drug delivery represents a key advancement in cancer therapy.